The prices of 8 drugs were hiked without proof of new benefits, report finds; Sales of antibiotics used in food-producing livestock rose last year

Taking stock of the drug industry, from the lab to the medicine chest

December 11, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds Topping the list was AbbVie's Humira, for which spending rose $386 million after the list price rose 7.1%, although the net price rose 1.9% By Ed Silverman STAT+ | Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year The increase has prompted advocates to complain that not enough is being done to thwart antibiotic resistance. By Ed Silverman STAT+ | Inside Vertex's decades-long quest to develop a new class of non-opioid painkillers Vertex is about to announce results from late-stage trials of a drug that precisely blocks pain-sensing neurons from signaling the brain. By Jonathan Wosen Thibault Camus/AP STAT+ | Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns This is only the latest instance in which the Federal Trade Commission sought to reign in the pharmaceutical industry. By Ed Silverman STAT+ | A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk STAT sat down with Boger to discuss how Vertex began working in sickle cell disease, what he thinks the future holds for biotech, and more. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser